EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for the quarter ending 2024-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2025 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2023 was $8.90M, a 8800.00% increase from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, after tax for fiscal 2022 was $100.00K, a 98.28% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-27 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $5.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $5.30M derived: sum of 3 quarters · filed 2026-02-27 | $8.40M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 | $5.30M derived: sum of 2 quarters · filed 2026-02-27 | $8.40M derived: sum of 3 quarters · filed 2026-02-27 | $11.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.40M derived: sum of 2 quarters · filed 2026-02-27 | $11.30M derived: sum of 3 quarters · filed 2026-02-27 | $8.90M 10-K · filed 2026-02-27 |
| 2023-09-30 | $3.10M 10-Q · filed 2024-11-07 | $6.00M derived: sum of 2 quarters · filed 2024-11-07 | $3.60M 10-Q · filed 2024-11-07 | $5.60M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $2.90M 10-Q · filed 2024-08-07 | $500.00K 10-Q · filed 2024-08-07 | $2.50M derived: sum of 3 quarters · filed 2025-03-04 | $2.90M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$2.40M 10-Q · filed 2024-05-02 | -$400.00K derived: sum of 2 quarters · filed 2025-03-04 | $0.00 derived: sum of 3 quarters · filed 2025-03-04 | -$900.00K derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $2.40M derived: sum of 2 quarters · filed 2025-03-04 | $1.50M derived: sum of 3 quarters · filed 2025-03-04 | $100.00K 10-K · filed 2025-03-04 |
| 2022-09-30 | $400.00K 10-Q · filed 2023-12-11 | -$500.00K derived: sum of 2 quarters · filed 2023-12-11 | -$1.90M 10-Q · filed 2023-12-11 | |
| 2022-06-30 | -$900.00K 10-Q · filed 2023-08-09 | -$2.30M 10-Q · filed 2023-08-09 | ||
| 2021-12-31 | $5.80M 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |